Data mount for Xtent's customisable DES (drug-eluting stent)
This article was originally published in Clinica
Executive Summary
The first drug-eluting stent (DES) that can be customised in-situ has produced positive eight-month follow-up results in a feasibility and safety trial of the device for preventing coronary artery restenosis.